Stakeholders' recommendations for revising Good Clinical Practice.

Clinical trials Ethics Good clinical practice ICH E6 GCP Regulatory Stakeholders

Journal

Contemporary clinical trials communications
ISSN: 2451-8654
Titre abrégé: Contemp Clin Trials Commun
Pays: Netherlands
ID NLM: 101671157

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 15 09 2020
revised: 31 03 2021
accepted: 11 04 2021
entrez: 17 5 2021
pubmed: 18 5 2021
medline: 18 5 2021
Statut: epublish

Résumé

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is revising ICH E6 Good Clinical Practice (GCP). The Clinical Trials Transformation Initiative (CTTI) initiated a project to identify and provide ICH with stakeholders' priority areas and suggestions for revising ICH E6 GCP. We conducted a global online survey to identify areas of ICH E6 GCP that are and are not in need of revision. A total of 327 stakeholders completed the survey. Stakeholders represent many research roles and types of organizations, are employed in 39 countries, and conduct research in 153 countries. The ICH E6 GCP principles mentioned most often (range, 25%-29%) in need of revision were implementing systems that assure quality, providing medical care by qualified physicians/dentists, protecting confidentiality and privacy, obtaining informed consent, and documenting and storing information. The Investigator section (n = 244, 75%) and Sponsor section (n = 242, 74%) of ICH E6 GCP were identified as needing the most revision and the Investigator Brochure section (n = 166, 51%) as needing the least revision. The topic most frequently mentioned as needing revision is Monitoring (n = 146; 45%) in the Sponsor section. Although none of the principles or topics in ICH E6 GCP were identified as needing revision by the majority of stakeholders, a meaningful percentage of stakeholders identified areas that they believe need revision. These findings, which represent the views of a wide variety of stakeholders, may be useful to ICH for identifying where specifically to focus their revision efforts. CTTI provided the final report to ICH with the project findings for their consideration.

Identifiants

pubmed: 33997463
doi: 10.1016/j.conctc.2021.100776
pii: S2451-8654(21)00077-6
pmc: PMC8100063
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100776

Subventions

Organisme : FDA HHS
ID : R18 FD005292
Pays : United States
Organisme : FDA HHS
ID : U18 FD005292
Pays : United States

Informations de copyright

© 2021 The Authors.

Déclaration de conflit d'intérêts

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

Auteurs

Amy Corneli (A)

Clinical Trials Transformation Initiative, Duke University, Durham, NC, USA.
Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.

Annemarie Forrest (A)

Clinical Trials Transformation Initiative, Duke University, Durham, NC, USA.

Teresa Swezey (T)

Clinical Trials Transformation Initiative, Duke University, Durham, NC, USA.
Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.

Li Lin (L)

Clinical Trials Transformation Initiative, Duke University, Durham, NC, USA.
Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.

Pamela Tenaerts (P)

Clinical Trials Transformation Initiative, Duke University, Durham, NC, USA.

Classifications MeSH